BioPharma Clinical Trials

RVAC Medicines Initiates First-in-Human Clinical Trials for mRNA COVID-19 Vaccine Candidates

The Phase 1 study is an open-label, dose escalation study to evaluate the safety and immunogenicity of RVM-V001 in approximately 54 healthy adults in ...

 September 23, 2022 | News

Menarini and SciClone to Develop and Commercialize Vaborem® in China to Treat Antimicrobial Resistant Infections

Vaborem®, a patented combination of meropenem and vaborbactam, is expected to address the rising prevalence of carbapenem-resistant Klebsiella pneumo...

 September 21, 2022 | News

Qurient Announces Collaboration Agreement with MSD

Q901 is a novel highly selective CDK7 inhibitor Q901 is ready for dose escalation study in the U.S. for the treatment of selected advanced solid tumors ...

 September 19, 2022 | News

Merck announced that the IAP (inhibitor of apoptosis protein) inhibitor xevinapant (formerly known as Debio 1143) plus chemoradiotherapy (CRT) markedly improved long-term efficacy outcomes in patients

First randomized trial in decades to show significant improvement in overall survival in patients with LA SCCHN, reinforcing the transformative potential...

 September 14, 2022 | News

Cytel expansion unlocks innovative clinical trial capabilities for APAC biopharma sector

This enables biotech and biopharma companies in APAC to have easier access to Cytel’s established biometrics and advanced statistical solutions. For ...

 September 07, 2022 | News

Jacobio Completes First Patient Dosage of CD73 mAb JAB-BX102 in China

This is a phase I/IIa multi-center, open-label clinical study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of anti-tumo...

 September 05, 2022 | News

EpiEndo Commences LPS Challenge Trial for Lead Candidate EP395

 EpiEndo Pharmaceuticals (‘EpiEndo’), the clinical-stage biopharmaceutical company developing disease-modifying therapeutics for chro...

 September 01, 2022 | News

Nuance Pharma Announces Clearance of IND Application for Ensifentrine Pivotal Clinical Trials for COPD in China

Ensifentrine is a first-in-class, dual inhibitor of the enzymes phosphodiesterase 3 and 4 ("PDE3" and "PDE4") combining bronchodilator and anti-inflam...

 August 21, 2022 | News

Bridge Biotherapeutics Receives FDA Authorization to Proceed with Phase 2 Study of BBT-877

Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotechnology company developing novel drugs for cancer, fibrosis and inflammation, announ...

 August 17, 2022 | News

Recbio announces Phase III Clinical Trial Progress Of Recombinant HPV 9-Valent Vaccine

The phase III clinical trial of REC603 in China consists of three parts, i.e. the efficacy trial, the immuno-bridging trial in younger-age groups...

 August 11, 2022 | News

Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

-Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vacc...

 August 09, 2022 | News

Innovent Biologics and Sanofi Enter Strategic Collaboration to Accelerate Development of Oncology Medicines and Expand Presence in China

Collaboration to accelerate the development and access of oncology medicines for cancer patients in China Clinical trial programs combining two of ...

 August 05, 2022 | News

LG Chem Enters Final Stage of Clinical Development for New Gout Drug

In global Phase 3 clinical trial, Tigulixostat will be evaluated in 350 adult gout patients with hyperuricemia for safety and efficacy at Month 6 of treatm...

 August 04, 2022 | News

Lynk Pharmaceuticals Announces First Participants in Phase I Trial of LNK01004

This study is to evaluate the safety, tolerability, and pharmacokinetics of the LNK01004 ointment in healthy adults and patients with mild to moderate plaq...

 July 29, 2022 | News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in